Department of Cell and Developmental Biology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
Trends Mol Med. 2011 Aug;17(8):412-23. doi: 10.1016/j.molmed.2011.04.003. Epub 2011 Jun 7.
The field of pharmacogenomics aims to predict which drugs will be most effective and safe for a particular individual based on their genome sequence or expression profile, thereby allowing personalized treatment. The bulk of pharmacogenomic research has focused on the role of single nucleotide polymorphisms, copy number variations or differences in gene expression levels of drug metabolizing or transporting genes and drug targets. In this review paper, we focus instead on microRNAs (miRNAs): small noncoding RNAs, prevalent in metazoans, that negatively regulate gene expression in many cellular processes. We discuss how miRNAs, by regulating the expression of pharmacogenomic-related genes, can play a pivotal role in drug efficacy and toxicity and have potential clinical implications for personalized medicine.
药物基因组学领域旨在根据个体的基因组序列或表达谱预测哪些药物最有效和安全，从而实现个体化治疗。大量的药物基因组学研究集中在单核苷酸多态性、拷贝数变异或药物代谢或转运基因和药物靶点的基因表达水平的差异上。在这篇综述论文中，我们将重点介绍 microRNAs（miRNAs）：真核生物中普遍存在的小非编码 RNA，可在许多细胞过程中负调控基因表达。我们讨论了 miRNA 通过调节与药物基因组学相关的基因表达，如何在药物疗效和毒性中发挥关键作用，并为个性化医学提供潜在的临床意义。
